1. Dysphoria, dopaminergic medication and spatial memory in Parkinsons disease
- Author
-
er Storch, Ricarda Evens, Oliver Riedel, Mareike Fauser, Franka Thurm, Alex, Shu-Chen Li, Ulrike Lueken, and Yuliya Stankevich
- Subjects
medicine.medical_specialty ,Dopaminergic ,Cognition ,Disease ,medicine.disease ,Dysphoria ,Psychiatry and Mental health ,Dopamine ,medicine ,Dementia ,Neurology (clinical) ,medicine.symptom ,Psychology ,Psychiatry ,Depression (differential diagnoses) ,Depressive symptoms ,medicine.drug - Abstract
Depression is considered a potential risk factor for developing cognitive deficits and dementia during the progression of Parkinson’s disease (PD). Depression and dysthymia are also among the most frequent neuropsychiatric comorbidities, especially in later stages of PD. Regardless of the depression diagnosis, clinical and subsyndromal depressive symptoms in PD patients are associated with decreased daily functioning. However, very little is known about subsyndromal depressive symptoms and their relations to cognitive function and dopamine medication in PD. Here we investigated depressive symptoms and spatial memory performance in 34 early PD patients compared to 36 matched healthy controls in a pharmacobehavioral cross-over study.
- Published
- 2018